Literature DB >> 2410943

Development of tolerance to the wet-dog shake behaviour but not the increase in seizure threshold induced by L-5-hydroxytryptophan during continued treatment in rats.

S R Pagliusi, W Löscher.   

Abstract

The time course of different pharmacological effects of L-5-hydroxytryptophan (5-HTP) during continued treatment was studied in rats. 5-HTP was administered three times daily at 100 mg/kg IP in combination with the peripheral decarboxylase inhibitor carbidopa (10 mg/kg) for 14 days. 5-HTP induced a pronounced increase of the threshold for maximal electroconvulsions, decreased body temperature and body weight and induced characteristic "wet-dog" shake behaviour. Whereas the anticonvulsant effect increased during the 14 days of treatment, tolerance developed to the excitatory and, less rapidly, to the hypothermic and anorexigenic effects of 5-HTP. Biochemical determinations showed marked increases in 5-HTP and its metabolites, 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid, in both plasma and brain throughout the period of treatment. The mechanisms underlying the different time-courses of the functional effects of 5-HTP during continued treatment are not clear, but effects on catecholaminergic systems as well as regional differences in 5-HT increases in the brain might be involved.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410943     DOI: 10.1007/bf00431695

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  Chemical protection against ionizing radiation. I. Sampling methods for screening compounds in radiation protection studies with mice.

Authors:  A W KIMBALL; W T BURNETT; D G DOHERTY
Journal:  Radiat Res       Date:  1957-07       Impact factor: 2.841

2.  [Influence of changes of serotonin content of the central nervous system on the seizure threshold of cardiazol].

Authors:  W KOBINGER
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1958

3.  On the interaction of 5-hydroxytryptophan and 5-hydroxytryptamine with dopamine metabolism in the rat striatum.

Authors:  N Awazi; H C Guldberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-05       Impact factor: 3.000

4.  "Wet-dog" shake behaviour in the rat: a possible quantitative model of central 5-hydroxytryptamine activity.

Authors:  P Bedard; C J Pycock
Journal:  Neuropharmacology       Date:  1977-10       Impact factor: 5.250

5.  Central monoamines and convulsine thresholds in mice and rats.

Authors:  M Kilian; H H Frey
Journal:  Neuropharmacology       Date:  1973-07       Impact factor: 5.250

6.  p-Chlorophenylalanine: a specific depletor of brain serotonin.

Authors:  B K Koe; A Weissman
Journal:  J Pharmacol Exp Ther       Date:  1966-12       Impact factor: 4.030

Review 7.  Cellular compartments of GABA in brain and their relationship to anticonvulsant activity.

Authors:  M J Iadarola; K Gale
Journal:  Mol Cell Biochem       Date:  1981-09-25       Impact factor: 3.396

8.  L-5-hydroxytryptophan. Correlation between anticonvulsant effect and increases in levels of 5-hydroxyindoles in plasma and brain.

Authors:  W Löscher; S R Pagliusi; F Müller
Journal:  Neuropharmacology       Date:  1984-09       Impact factor: 5.250

9.  Tolerance to the increased locomotor activity produced by L-5-hydroxytryptophan following peripheral decarboxylase inhibition in mice.

Authors:  R L Magyar; J C Gillin; R J Wyatt
Journal:  Psychopharmacology (Berl)       Date:  1978-04-11       Impact factor: 4.530

10.  Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man.

Authors:  I Magnussen; T S Jensen; J H Rand; M H Van Woert
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1981-09
View more
  1 in total

1.  The behavioural responses to 8-OH-DPAT, ipsapirone and the novel 5-HT1A receptor agonist Bay Vq 7813 in the pig.

Authors:  W Löscher; U Witte; G Fredow; J Traber; T Glaser
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-09       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.